Stockpolly
Search
AVIR · NASDAQ · Biotechnology

Atea Pharmaceuticals (AVIR)

Develops oral antiviral candidates for HCV and HEV infections.

$5.73
Pre-market+0.03 (+0.44%)
At close$5.71(+3.92%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue180002003238000
Gross profit−18000−200−3−2−38000
23467047173936397554835
Research & development323558352626303238484128
131112121113997777
Selling & marketing000000000000
General & administrative13121212110997777
Other expenses−22000−200−3−2−38000
Operating income−41−47−70−47−37−39−39−41−46−55−48−35
887766544332
Interest income887766544330
Other non-operating income−10−8−7−7−6−6−50−4−3−3−2
Income before tax−33−39−63−40−31−33−34−37−42−52−45−33
Income tax expense000000000−700
Net income from continuing operations−33−39−63−41−31−34−34−37−42−45−45−33
Net income−33−39−63−41−31−34−34−37−42−45−45−33
EPS, basic−$0.40−$0.47−$0.75−$0.48−$0.37−$0.40−$0.40−$0.44−$0.53−$0.57−$0.57−$0.41
EPS, diluted−$0.40−$0.47−$0.75−$0.48−$0.37−$0.40−$0.40−$0.44−$0.53−$0.57−$0.57−$0.41
Weighted average shares, basic838384848484858479787980
Weighted average shares, diluted838384848484858479787980
EBITDA−31−39−63−40−31−33−34−41−42−52−45−33
Depreciation & amortization000000000000
EBIT−31−39−63−40−31−33−34−41−42−52−45−33